Agios/$AGIO

13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1Y5YMAX

About Agios

Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.

Ticker

$AGIO
Primary listing

Industry

Biotechnology

Employees

487

ISIN

US00847X1046

Agios Metrics

BasicAdvanced
$2.1B
3.15
$11.45
0.73
-

What the Analysts think about Agios

Analyst ratings (Buy, Hold, Sell) for Agios stock.

Bulls say / Bears say

Agios Pharmaceuticals' lead product, PYRUKYND® (mitapivat), generated $8.7 million in net revenue in Q1 2025, up from $8.2 million in Q1 2024, indicating steady growth in its commercial performance. (Agios Pharmaceuticals Press Release)
The European Commission granted orphan medicinal product designation to mitapivat for the treatment of sickle cell disease, providing benefits such as reduced fees and 10-year market exclusivity, which could enhance the drug's market potential in Europe. (StockTitan)
Analysts have shown confidence in Agios Pharmaceuticals, with Scotiabank raising its price target from $53.00 to $75.00 and assigning a 'sector outperform' rating, reflecting positive expectations for the company's future performance. (Defense World)
Agios Pharmaceuticals reported a net loss of $89.3 million for Q1 2025, compared to $81.5 million in Q1 2024, indicating increasing operational losses that may concern investors. (Agios Pharmaceuticals Press Release)
The departure of Dr. David P. Schenkein from the Board of Directors, effective February 28, 2025, could lead to uncertainties regarding the company's strategic direction and leadership stability. (Investing.com)
Insider selling activity, such as Chief Commercial Officer Tsveta Milanova selling 2,804 shares worth $90,232 in January 2025, might signal a lack of confidence in the company's short-term stock performance. (Investing.com)
Data summarised monthly by Lightyear AI. Last updated on 6 Jul 2025.

Agios Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Agios Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $AGIO

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs